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U. Elkapm: Dr. Pitt, was the need to start an&en& 
converthtg enxyme inhibitors an end point in the SOLVD 
study? 
~PittrWelookedattheneedfuraddhio&heartfailun 
therapy, inchldh& the need for die and conveltinlg 
enxyme inhibitors. Both were required more frequently in 
theenalaprilgroupthallhltheplacebogroup. 
~CedyrDr.Eenedict,Iamimpressedbytwoobserva- 
tions.Pirst,withfewexceptioas,plasma~ne 
ievelsinhoththeSOLVDandtheSAVEtrialswerewithin 
thenarmal~.!3eWlld,despitethenorlMlhonnonal 
b&round, @oten4n-convertinq e xyme inhibitors pro- 
ducedafavomblee&ctthatf&wceededwhatmostinves- 
tigauwswouldhaveprediiinearlyheartfaihuw.Given 
theseobservations,whatistheroleofmeasuringphwm 
~ievelsinthefuture? 
c.ItsHlk&Letmerespondtoyour6r!3tquestion.The 
. 
wwepnnepbrinelevelsintheSoLVDpreventilmtrialpa- 
tientsarecloaertonormalthsnthelevelsintheSOLVD 
tmatmemtrial.However,theleveisinboth~upswere 
si@&amlyhi$lerthanvahlesincontrol~. 
&YmEItistruethatthemeanlevelsofneurohormones 
are &ni&mtly h&v in the SOLVD trials. However, only 
amiwrityofpatiemsintheSOLVDtrialshadrvahtethatis 
~1SD~atertbanthemeenofthecontrol~.Itis 
possiblethatourde6nitionofnormalshoaldheloweredor, 
altern&ely,onlyaminerityofpatientsexhiiactivationof 
theneurohonmmalsystem. Itwouldbehtterestinqtounder- 
stand this he&reg@ty. 
c. Bmsdktr Ahhough mean level!3 were relatively low, 
therearemanypatientswhohaveveryhi&neurohonmraa 
values.CouMsuchpatiemsbe~andstudiedprospec- 
timely infuture trials? By sele&g such patients, we may be 
able to conduct trials with fewer patients. 
B. pltt: In response toDr. Cody’s comments, phMma 
tenin levels in the SOLVD prevention trial were low, but 
~~l~el!5~~atmst.Rrhapi,reninlevelsia 
patientswithheartGhuewouldbemoreeasilydistin- 
euisheafromplaceboiftbeyweremeasmedduringexe+se. 
M. plleba: Dr. Bmedict, you analyxed the predictive 
wdueofbasehnenwrohannonal Btsinallofthe 
~in~saudy,butIamnotsuIethatthisisthecorrect 
appmach. It is important to look at the predictive &es of 
baseline measurements o lyin the patients who received 
placebo. To the extent hat activation of the renin- 
angiotensin ystem plays an important role in the progwz+ 
sion of heart failure, we might expect plasma renin activity 
to predict survival in such patients (as other studies have 
shown). However, since the influence of the renin- 
~systemwouldbeblockedinpatientsreceivinga 
convertingenxymeinhibitor,wewouldnotexpectplasma 
reni  activity to predict sun&al in patients receiving enala- 
pril. Support for my point comes iiom the CONSENSUS 
trial. In that study, values for plasma renin activity at the 
meofentryintothestudypredi&dsurvivalinthepatients 
. 
~toplacebo,butnotinthoseraudomixedto 
en@ril.AsimikwanalysisshouMbecarriedoutinthe 
patients enrolled in the SOLVD trial. If you look at the 
~4redi&vvaiaiofba!H+c measluements forali patients 
ra&mued to placebo and enalapril), you 
lose the ability to detect important cor&tions in speci6c 
subguMs* 
J.CehmThepointthatDr.Packerjustmadeabuutrenin 
istrue.Reninisaunivariatepredi&rofsurvivalinthe 
placebo arm and even in the twubnent arm, but in our 
expwience,itisnotapredictorhtamultivariatemodel, 
whenyouconsMernorephEphrineconcomitantly. 
M. prta: The predictive alue ofnemohormomd mea- 
smemeMsmaydependonthepatientpop&tionbeing 
evakMed.Inpatientswithmildtomodemteheartfaihue, 
plasmanonpiaephriaeisamorepmveMpredictorof 
survivalthanisplasmareniaactivity.Incon&ast,inour 
expe ienaendintbataiDr.JeanRouleau~tbeUniver- 
sityofSher6rodre,plasmamninactivityisthemostpower- 
fulpredictorofsurvivalinpatientswithseverehefuttuihue. 
J.caba:Ifyoustudypatientsinf&thmaiclassIV,I 
aqree with you completely. 
lbi. Peeler: I think it is worth emphasizing that the 
systemsusedtoclassifythemodeofdeathinpatientswith 
chronicheartibihuearevagveatbestandarbitraryatworst. 
N~~,itisimportanttomaLes~thatallofthcdata 
hlaIGltdividludtrhd~WllectedUsingunaOrmcriteria 
lllat~whyitisessentialthatthe~ofmorudity 
~byeachinve@puorbereviewedbyacentral 
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committee that uses prospectively defined criteria. A central 
committee r viewed all of the mortality data in the V-HeFI’ 
and SAVE trials but not in the SOLVD trial. In the SAVE 
trial, the Mortality Classikation Committee moditied onc- 
third of the mortality classification decisions made by the 
investigators. 
J. Cohut The Mortality Ciasstication Committee changed 
about 25% of the decisions of the investigators in the 
V-HeFT study. 
S. Yut& Who is right? The wmmittec or the investiga- 
tor7 
J. C&u There are problems when a trial relies on the 
classification of the investigator without oversight by a 
central wmmittee. Investigators donot use uniform criteria 
and are often inlluenced by extraneous physiologic data; for 
example. they will classify the death of a patient with a low 
ejection fraction as due to progressive h art failure ven it is 
sudden. Knowing the ejection fraction influences the classi- 
fication. I think we need to be very cautious about reaching 
conclusions about he mechanism ofdeath when the classi- 
fication system varies from study to study. 
S. Yusufr Whatever your wncems may be, I would 
emphasize that the results of three huge, randomized trials 
that compare an angiotensin~nverting enzyme inhiitor 
with placebo are hiihly consistent. The CONSENSUS study 
and both of the SOLVD trials showed that converting 
enzyme inhibition reduced the risk of pump ftilure but not of 
sudden death. DitTerences in classification in a blinded trial 
should be unbiased and can blur a diietence, but they should 
not chaDge the results if a difference is observed. In the 
SOLVD treatment and prevention trials, there was a small 
reduction (about 8%) in the risk of sudden death. From these 
data, you cannot conclude that there is no elfect on sudden 
death. You can conclude only that he effect is much smaller 
than the e&t on pump failure deaths. In the SOLVD trials 
there were 148 nonfatal cases of documented cardiac arrest, 
74 each in the enalaprR and placebo groups. In the SOLVD 
trials, enalaprR had no effect on the risk of death that 
occurred without prior hospitalizations for heart thilure. 
These three observations are congruent and indicate that 
angiotensin+zonvert@ nzyme inhibitors do not reduce the 
incidence of sudden death. The only logical explanation for 
the differences seen between the V-HeFI’ II study and all 
placebo-controlled trials of angiotensinconverting e zyme 
inhibitors was that he V-Hem II study compared enalapril 
with active agents rather than placebo. 
J. CeIuu I agree with your observations, but they are 
based on a se&fb@lling prophecy if 75% to 80% of your 
deaths are due to pump failure. Hence, it is impossible to 
detect an efkct of a drug on sudden death if so fkw patients 
die suddenly. If half of the patients had died suddenly, ou 
would have had a better chance of Wing an efkct on 
sudden death. 
B. Phti In the SOLVD prevention trial, half of the cardiac 
deaths were sudden, and the small treatment benefit we 
observed was due to a reduction i  death from progressive 
heart failure and not to a reduction i  sudden death. 
~~Iwwo~ldliketogobacktomechsnisms.lone 
looks for an explanation as to why angiotensin-converting 
enzyme inhibitors are more &ctive than other vm 
it is possible that these drugs act to prevent or to slow 
maladaptive growth processes. If converting enzyme inhib- 
itors are acting as growth lhiitors, then one might plx!dict 
that if they are given early in the course of myocardkd 
infarction (that is, in the iirst few hours), when hypertrophy 
is probably more adaptive than mahu@tive, oae could see a 
detrimental effect rather than a bet&51 etfect ofthe drug. 
This has been reported from the Maastricht group (Schoe- 
maker RG, Debets JJM, Struyker Boudier HA& &nits JIM. 
Delayed but not immediate herapy improves cardiac func- 
tion in conscious rats following myoca&l i&ction. J I&l 
Cell Cardiol 1991;23:187-). These data are supported 
clinically by the results of the CONSENSUS II study. 
M. PR#err When we first started our work on ventricular 
remodeling, we found that the results were similar if we 
intervened after 2 days or after 14 days but the regults mi&t 
have been d&rent if we had intervened during the hyper- 
acute phase ofmyocardial infarction. Dr. Cohn’s tudy with 
nitroprusside showed that the effects of the drug were 
dependent on the timing of the intervention. Hence, I am 
wncerned about producing hypotension day 1 of an acute 
myocardial infarction, but I do not think this is related to the 
inhibition of hypertrophy. 
E. SonumhI& I believe that during the acute phase of 
myoca&l i&r&on (when there is early remodeling) there 
is a loss of cells resulting from the acute distension. That is 
why I think you need to intervene as early as possible and 
prevent as much of the remodeling as you can, because 
probably half of your remodeling takes place within the 1st 
week. 1 think we need to intervene ariier to prevent 
remodeling, slippage of cells and loss of cells and not just to 
prevent the expansion ofthe infarction. 
M. Pf&rr But then you have the risk of very early 
intervention, asDr. Ratx emphasized. I do not think we will 
understand the trade-off of bene6t and risk in the early 
phasesofanacute5farctionuntilwecarryoutatrialthat 
comparesearlyand&layedinterventkmwithanaagiolensia_ 
converting enzyme inhibitor. We are planoing to carry out 
suchastudythatwillcomparetheeffectsafaconveaiag 
enxymeinhib&administeredondayIwiththoseofa 
converting enzyme inhibitor administered on day 14 after an 
acute myocardial in&tion. This trial will have an echocar- 
diographic end point. 
M.BackrzIamstruckbythethctthatnoonehas~ 
a question about Dr. Yusufs provocative m that 
cotwert&enxyme inhibitors hould be ewduated for their 
ebility to prevent recurrent ischemic events in all patients 
whohavehadanacutemyocatdiaIinfan+n.This~~ 
i~~m~t.hg idea, but I can foresee a problem. If aspirin 
attenuates the effects of convertinq e Uyme ~ihitors9 how 
wiRwebeabletoshowthatwnVertinqenYme~itors 
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~cetberiskdr4&ction,becausemostoftbepatients 
receiving converting enzyme iubibitors are also receiving 
aSpKIt? 
5.YaadfInmyview,tbereisnobasisfor$le~mtbat 
aspirin i hibits tbe e&t of aa@ensin-converting enzyme 
i&bitors.If~focllsolltbeendpoifltsilltbeSOLVDtrisl 
wberetmatmentappearstobaveamadedi&sence(thatis, 
pumplbiiureaudmyocsrdialb&ction),tb~isnoevidence 
ofaniatem&m.TheinMactioaappearstoheIebltedtoan 
mmsual distriition of nancardiac deatbs and I believe 
representsast&&caiquirk.IwouIdbeinterestedinseeing 
wbattbeSAVEtriaisbows,because6O%ofthepatientsia 
that study were receivii aspirin. 
RdPa&!r:Dr.Pfe&r,doweknowiftherewasan 
intenMionhetweenaspirinandcaptoprilintbeSAVEtriai? 
IK.PMbr:Wedoaotknowtbatyet. 
M. Far&: We wiii await be resuits with in-St. Is 
anyone thing about canyb out a deibdtive s co&ry 
mention trial witb a converting enxyme i&ii 
B.Pi&Thereisonesucbtriaiinprogress.TheQuin@ 
Ischemic Event Triai (QUIET) is explor@ the e&ct of 
ar@otensin-convertiag enzyme inbibitors on iscbemic 
eventsinpatientswitbapresen&ieftvemrMar ’ ’ 
fractionwbobavereoentiyo&rgonecaonaryangi~~ 
App~~~ximately 1,700 pa&nts have been enmiled in tbe 
study and are m flowed up for ischemic events. In a 
subsetof60opatients,seriaiangiogRunsarepufoH&to 
look for an&graphic evidace of &seasc pmgmsion. 
J.coLn:0rleprovocanveobservationistbatenalepril 
leducedtheriskof murent iscbemic events. However, in
both the V-HeFT and the SOLVD treatment trials, enaiaprii 
tendedtobemoreeifectiveinpatient!Mthnonischemic 
cardiomyopathy thanin those with iscbemic M disease, 
ahhougb the interaction was not quite sigo&ant. It rrrise~ 
the possiiity tbat tbe benefit of a@otensin-converting 
enxymeiobi&itorsinpatientswitbiscbemicbeartfailrrremay 
be ia@y reiated to tbe reduction ofiscbemic events and 
tbat be drug may be acting by a d&rent mechanism in 
patients with nonischemic heart disease. 
M.~WbydidtbeSOLVDtriaisbowareductionin 
tbe risk ofrei&ction with enai&l in patients who did not 
bave wronary artery disease? 
& YIIS& Many patients with noniscbemic heart disease 
badioag4andingbypertensionandtbeiraverageagewasti0 
years. Hence, some may have bad siient coronary artery 
disease. Incidentaiiy, were data on myocardii nfarction 
collected in tbe V-HeFT II study? 
J. coba: Yes, but the number ofevents was quite small. 
G. (;rjlst: I am impressed by tbe low proportiw of 
people in the triais who were receiving aspirin and beta- 
blockers, because these d~B3 should bave been indicated in 
most of the patients enrolled inthese studies. It is wonderfui 
to show effects in ciii trials. but unless physicius use 
drags of established worth, these studies wiii not have much 
of an impact. Isthere an explanation f r tbe relatively low 
use of aspirin and beta-blockers in these trials? 
IbCPB&rzIntbeSAVEtriai,=46%oftbepatientswere 
receiw aspirin, anotber 15% were tak& other antipiatelet 
drugs, 30% were prescribed coumadin at tbe time ofenroii- 
ment into the study. In contrast, despite evidence of benefit, 
only one third of our patients wee receiving a beta-blocker. 
8. FIt& In the SOLVD trial, a third of tbe patients with a 
low ejection fraction were receiv@ first-generation calcium 
channel b ockers, although t e available triai data indicate 
tbat his is not the right thiq to do. 
M.Pldrrr:Wewouidiiketotbinktbattbeinvestigators 
in the SOLVD, SAVE and V-HeIT triais wouid have 
Mblbily translated the conclusions from earlier studies into 
cihdcai practice. 
